The global leukapheresis market size was valued at USD 621.4 million in 2025 and is projected to grow from USD 665.0 million in 2026 to USD 1,059.3 million by 2034, exhibiting a CAGR of 6.0% during the forecast period. North America dominated the leukapheresis market with a market share of 36.71% in 2025.
Continue reading for more details:
https://www.fortunebusinessinsights.com/leukapheresis-market-115796
Market Segmentation
The global leukapheresis market is analyzed across multiple segmentation categories through 2026 to capture demand dynamics and application trends. By product type, the market divides into instruments and consumables, with consumables holding the largest share due to ongoing requirements for each procedure and the rising number of hematopoietic stem cell transplants that depend on leukapheresis consumables for safe and efficient cell separation. Under procedure type, the market is segmented into donor leukapheresis and therapeutic leukapheresis, where therapeutic leukapheresis accounts for a dominant portion of the market owing to its critical role in managing leukemia and other hematological disorders that require regular removal of white blood cells from patient circulation. In terms of technology platform, centrifugation systems overwhelmingly lead the market because of their established efficiency, ability to process larger blood volumes, and accuracy in isolating specific cell populations, while membrane filtration systems are gaining traction as complementary options. The end‑user segmentation includes hospitals, specialty clinics, blood collection centers & blood banks, and other healthcare facilities, with hospitals expected to retain the largest share of the leukapheresis market through 2026 as they provide broad clinical services and perform the majority of advanced therapeutic procedures involving leukapheresis. This comprehensive segmentation reflects how different aspects of leukapheresis — from device type and procedure variations to technology and application settings — collectively influence clinical adoption and investment decisions across the healthcare continuum. The segmentation framework underscores the multifaceted nature of the leukapheresis market and its dependence on evolving medical needs and institutional capabilities.
Key Players
Here are some of the principal companies shaping competition and driving innovation in the leukapheresis market:
• Fresenius SE & Co. KGaA
• Haemonetics Corporation
• Terumo Corporation
• Asahi Kasei Medical Co., Ltd.
• Lonza
• Charles River Laboratories
• AllCells
• STEMCELL Technologies
• Miltenyi Biotec
• Macopharma
Market Growth
The global leukapheresis market is projected to grow steadily between 2026 and beyond, with the market size anticipated to rise from approximately USD 665.0 million in 2026 to around USD 1,059.3 million by 2034, representing a robust compound annual growth rate of about 6.0 percent. This expansion reflects increasing prevalence of chronic diseases, particularly various forms of cancer and hematological disorders, which drive demand for therapeutic procedures that rely on leukapheresis for white blood cell removal and cell collection. In addition, the surge in CAR‑T cell therapy and other advanced immunotherapies that depend on leukapheresis as a critical first step in harvesting patient immune cells for genetic modification fuels the need for specialized products and services across clinical and research settings. Ongoing technological advancements — including automated flow control, real‑time monitoring, and improved cell separation algorithms — are enhancing procedure efficiency and boosting the utilization of leukapheresis systems globally. Growing government initiatives to support biotechnology development and expanded healthcare infrastructure in emerging economies are further contributing to market growth. Concurrently, increasing investments in research and development by major market players contribute to the introduction of novel devices and consumables that address unmet clinical needs, which in turn fosters adoption across hospitals, specialty clinics, and blood centers worldwide and reinforces the overall momentum in the leukapheresis market.
Restraining Factors
Despite strong growth prospects, there are notable restraining factors that may limit the pace of expansion in the leukapheresis market. One primary challenge is the high cost associated with leukapheresis procedures and the necessary infrastructure, including automated apheresis devices, monitoring systems, sterile disposable kits, and controlled processing environments. The significant capital investment required for establishing a leukapheresis unit may deter smaller hospitals or clinics from adopting these technologies, particularly in resource‑constrained regions. Moreover, reimbursement pressures remain significant in certain markets, as payers may be hesitant to cover the full procedural and device costs associated with therapeutic leukapheresis, thereby affecting utilization rates. The complexity of complying with stringent regulatory standards for cell and gene therapy collections adds additional financial and operational burdens for healthcare providers. In many low‑ and middle‑income countries, limited access to advanced healthcare infrastructure and trained professionals capable of performing leukapheresis further restricts market penetration. Challenges in maintaining strict cold‑chain logistics and ensuring consistent quality in processing environments also present operational hurdles that could slow adoption. These restraining factors underscore the need for cost‑effective solutions, supportive reimbursement policies, and expanded training initiatives to unlock the full potential of the global leukapheresis market.
Regional Analysis
Geographically, the leukapheresis market exhibits varied growth patterns across key regions, shaped by healthcare infrastructure, disease prevalence, and investment trends. North America remains the dominant regional market in terms of revenue and clinical adoption, largely driven by high incidence of chronic conditions, broad acceptance of advanced therapies like CAR‑T cell treatments, and robust reimbursement frameworks that support leukapheresis procedures. Within North America, the U.S. is projected to secure a significant share of global sales in 2026, reflecting strong demand and extensive healthcare capabilities. Europe follows as a major market, with advanced healthcare systems and technological readiness supporting steady growth; countries such as Germany and the U.K. are expected to contribute meaningfully to regional revenues. Asia Pacific is also emerging as a key growth region, with rising cancer rates, expanding biotech sectors, and improving healthcare infrastructure fostering increased deployment of leukapheresis solutions in markets such as China, Japan, and India. While Latin America and the Middle East & Africa represent smaller portions of the global leukapheresis market, these regions are anticipated to witness moderate growth due to expanding healthcare investments and heightened interest in research activities. Within Africa, the GCC countries are set to register incremental increases in market value, though challenges related to infrastructure and trained personnel remain. Overall, the regional analysis illustrates how differing economic and healthcare landscapes influence the adoption and integration of leukapheresis technologies, with developed regions maintaining dominance while emerging markets gradually expand their footprint in this evolving sector.